|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Hoffmann-La Roche |
|---|---|
| Information provided by: | Hoffmann-La Roche |
| ClinicalTrials.gov Identifier: | NCT00048945 |
Purpose
The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Hepatitis B |
Drug: PEGASYS |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Hide Study Locations| United States, Arizona | |
| Scottsdale, Arizona, United States, 85259 | |
| United States, California | |
| Los Angeles, California, United States, 90048 | |
| San Francisco, California, United States, 94115 | |
| Pasadena, California, United States, 91105 | |
| Downey, California, United States, 90242 | |
| United States, Georgia | |
| Atlanta, Georgia, United States, 30308 | |
| United States, Hawaii | |
| Honolulu, Hawaii, United States, 96817 | |
| United States, Massachusetts | |
| Boston, Massachusetts, United States, 02111 | |
| United States, Michigan | |
| Ann Arbor, Michigan, United States, 48109 | |
| United States, Minnesota | |
| Minneapolis, Minnesota, United States, 55404-4565 | |
| United States, Nebraska | |
| Lincoln, Nebraska, United States, 68501 | |
| United States, North Carolina | |
| Chapel Hill, North Carolina, United States, 27599-7080 | |
| United States, Texas | |
| Cedar Creek, Texas, United States, 78612 | |
| United States, Utah | |
| Salt Lake City, Utah, United States, 84121 | |
| United States, Washington | |
| Seattle, Washington, United States, 98195 | |
| Australia | |
| Concord, Australia, 2139 | |
| Herston, Australia, 4029 | |
| Brazil | |
| Sao Paulo, Brazil, 01246-900 | |
| Porto Alegre, Brazil, 90035-003 | |
| Campinas, Brazil, 13081-970 | |
| Salvador, Brazil, 40150-130 | |
| Canada, Alberta | |
| Calgary, Alberta, Canada, T2N 4N1 | |
| Canada, Ontario | |
| Toronto, Ontario, Canada, M5G 1X5 | |
| Toronto, Ontario, Canada, M5G 1L7 | |
| China | |
| Hong Kong, China | |
| Beijing, China, 100034 | |
| Beijing, China, 100039 | |
| Beijing, China, 100011 | |
| Chengdu, China, 610041 | |
| Beijing, China, 100050 | |
| Shanghai, China, 200025 | |
| Shanghai, China, 200040 | |
| Shanghai, China, 200433 | |
| Guangzhou, China, 510515 | |
| Guangzhou, China, 510630 | |
| Hangzhou, China, 310003 | |
| Beijing, China, 100054 | |
| Chongqing, China, 400010 | |
| France | |
| Lyon, France, 69288 | |
| Clichy, France, 92110 | |
| Germany | |
| Duesseldorf, Germany, 40225 | |
| Berlin, Germany, 13353 | |
| Muenchen, Germany, 81377 | |
| Hannover, Germany, 30623 | |
| Bochum, Germany, 44791 | |
| Koeln, Germany, 50931 | |
| Israel | |
| Haifa, Israel, 31096 | |
| Tel Aviv, Israel, 64239 | |
| Petach Tikva, Israel, 49100 | |
| Korea, Republic of | |
| Seoul, Korea, Republic of, 135-170 | |
| Seoul, Korea, Republic of, 138-736 | |
| Seoul, Korea, Republic of, 120-752 | |
| Seoul, Korea, Republic of, 150-713 | |
| New Zealand | |
| Otahuhu, New Zealand | |
| Poland | |
| Warszawa, Poland, 01-201 | |
| Bialystok, Poland, 15-540 | |
| Bydgoszcz, Poland, 85-030 | |
| Puerto Rico | |
| Santurce, Puerto Rico, 00909 | |
| Singapore | |
| Singapore, Singapore, 159402 | |
| Singapore, Singapore, 169608 | |
| Singapore, Singapore, 228510 | |
| Switzerland | |
| Basel, Switzerland, 4031 | |
| Taiwan | |
| Taipei, Taiwan | |
| Taipei, Taiwan, 100 | |
| Taipei, Taiwan, 114 | |
| Kaohsiung, Taiwan | |
| Tainan, Taiwan | |
| Kwei-Shan, Taiwan | |
| Thailand | |
| Bangkok, Thailand, 10700 | |
| Bangkok, Thailand, 10330 | |
| Bangkok, Thailand, 10400 | |
| Chiang Mai, Thailand, 50202 | |
| Songkla, Thailand, 90112 | |
| United Kingdom | |
| Nottingham, United Kingdom, NG2 3HF | |
More Information
| Study ID Numbers: | WV16240 |
| Study First Received: | November 12, 2002 |
| Last Updated: | August 11, 2005 |
| ClinicalTrials.gov Identifier: | NCT00048945 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Anti-Infective Agents Liver Diseases Hepatitis, Chronic Hepatitis, Viral, Human Hepadnaviridae Infections Antiviral Agents Pharmacologic Actions Hepatitis |
Virus Diseases Digestive System Diseases Therapeutic Uses Hepatitis B, Chronic Hepatitis B Peginterferon alfa-2a DNA Virus Infections |
